BioNTech SE (BNTX) AI Stock Analysis

• Market Cap: $22.92B
• Dividend Yield: N/A
• Average Volume (3M): 1.24M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.06
• Revenue Growth: 7.04%
• EPS Growth: -25.24%
• Country: US
• Employees: 6,772
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -1.43
• Shares Outstanding: 252,531,940
• 10 Day Avg. Volume: 2,496,064
• 30 Day Avg. Volume: 1,238,893
• PEG Ratio: -0.29
• Price to Book (P/B): 1.02
• Price to Sales (P/S): 7.10
• P/FCF Ratio: 72.58
• Enterprise Value/Market Cap: 0.55
• Enterprise Value/Revenue: 4.40
• Enterprise Value/Gross Profit: 5.66
• Enterprise Value/Ebitda: -19.83
• 1Y Price Target: $137.47
• Price Target Upside: 50.75% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 15
• EPS Forecast (FY): -3.76
• Revenue Forecast (FY): $2.35B

• Rating: 57 Neutral
• Price Target: $94.00 ▲(3.08% Upside)
• Action: Reiterated Date: 03/12/26
• Date: Action: Reiterated 03/12/26

The score is anchored by strong financial flexibility (low leverage and substantial resources) and constructive earnings-call updates (raised guidance and oncology progress), offset by weak current profitability and uneven cash generation. Technically, the stock is in a bearish trend below key moving averages, which further pressures the overall score, while valuation is inconclusive due to losses and no dividend yield data.

Positive Factors

Balance-sheet strength

A very low leverage profile and a large equity base provide durable financial flexibility to fund R&D, support late-stage trials, and absorb one-time hits. Over the next 2–6 months this reduces solvency risk, enables opportunistic M&A (e.g., CureVac) and limits refinancing pressure.

Structurally high gross margins

Consistently high gross margins indicate attractive core product economics and platform efficiency. This structural advantage can sustain unit profitability as commercial scale or new launches materialize, helping margins recover faster when revenue growth resumes.

Late-stage oncology pipeline & partnerships

An expanding late-stage oncology portfolio and strategic collaborations (e.g., BMS) create multiple mid-term commercialization paths. Registrational trials and prioritized programs increase the probability of near- to medium-term revenue diversification away from COVID-19, supporting a multi-product commercial transition.

Negative Factors

Profitability deterioration

The company swung from pandemic-era profits to a sizeable full-year loss driven by lower vaccine demand and higher operating costs. Persistent negative earnings strain retained earnings and complicate reinvestment choices; sustained losses could force reprioritization of programs or spending cuts.

Cash-flow volatility and weak conversion

Operating and free cash flow have been uneven, with a negative FCF year followed by a rebound. Weak cash conversion versus reported losses makes funding timelines for expensive Phase 3 programs less predictable and raises execution risk for near-term trial spend and launch preparation.

Management transition & governance change risk

Founders planning an independent mRNA venture and a phased management transition introduce execution and leadership continuity risk during a critical oncology pivot. Transfers of certain rights/technologies and organizational changes may affect R&D focus and partnership dynamics over the coming months.

BioNTech SE Business Overview & Revenue Model

Company Description

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, a preclinical stage product for non-small cell lung cancer. It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase 1a/1b clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 to treat solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II clinical trial to treat solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody in Phase II clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; and Regeneron Pharmaceuticals, Inc. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.

How the Company Makes Money

BioNTech makes money primarily by commercializing products and by partnering with larger pharmaceutical companies to develop, manufacture, and distribute its therapeutics and vaccines. A major revenue driver has been its collaboration with Pfizer to co-develop and commercialize the mRNA COVID-19 vaccine (Comirnaty), under which BioNTech earns revenue through a share of gross profit and other collaboration-related income tied to vaccine sales (including revenue from BioNTech’s territories and profit-sharing arrangements, depending on the market structure). Beyond COVID-19, BioNTech also generates revenue from strategic collaboration and licensing agreements—typically consisting of upfront payments, research funding, milestone payments tied to development/regulatory/commercial achievements, and potential royalties or profit-sharing on future product sales. The company may also earn revenue from manufacturing-related activities associated with its mRNA capabilities and supply obligations under partner agreements. Key factors influencing earnings include demand for COVID-19 boosters/variants, pricing and procurement dynamics across geographies, the allocation and terms of profit-sharing with partners, and the progression of its oncology and infectious disease pipeline that could trigger milestones or enable new commercial launches.

BioNTech SE Financial Statement Overview

Summary

Financial resilience is supported by a very strong, low-leverage balance sheet and structurally high gross margins, but profitability has deteriorated into losses with declining revenue, and cash flow has been volatile with only a modest rebound in 2025.

Income Statement

Profitability has deteriorated sharply as the business moved from very high earnings in 2021–2022 to losses in 2024–2025, with 2025 revenue down ~12.6% year over year and negative operating and net margins. A key positive is that gross margins remain structurally strong (roughly high-70% to mid-80% range), suggesting the core product economics are still attractive, but current scale and cost structure are not supporting bottom-line profitability.

Balance Sheet

The balance sheet is a major strength: leverage is very low (debt-to-equity ~1–3% across recent years) and equity remains large relative to assets, providing meaningful financial flexibility. The main weakness is returns have turned negative in 2024–2025 as losses reduced shareholder returns, but solvency risk appears limited given the modest debt load.

Cash Flow

Cash generation is mixed and volatile. After exceptionally strong operating and free cash flow in 2022–2023, 2024 saw negative free cash flow, followed by a return to positive free cash flow in 2025; however, cash conversion is currently weak versus profits because net income is negative and operating cash flow is modest relative to revenue. The rebound in 2025 is encouraging, but the recent swings highlight execution and demand uncertainty.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	2.76B	2.75B	3.82B	17.31B	18.98B
Gross Profit	2.14B	2.21B	3.22B	14.32B	16.07B
EBITDA	-256.17M	-367.10M	1.38B	13.10B	15.00B
Net Income	-1.09B	-665.30M	930.30M	9.43B	10.29B
Balance Sheet
Total Assets	21.98B	22.53B	23.01B	23.28B	15.83B
Cash, Cash Equivalents and Short-Term Investments	14.83B	16.78B	16.55B	14.06B	2.07B
Total Debt	267.29M	254.20M	219.10M	212.20M	301.50M
Total Liabilities	2.76B	3.12B	2.76B	3.22B	3.94B
Stockholders Equity	19.22B	19.41B	20.25B	20.06B	11.89B
Cash Flow
Free Cash Flow	269.81M	-244.60M	4.67B	13.21B	735.70M
Operating Cash Flow	438.00M	207.70M	5.37B	13.58B	889.70M
Investing Cash Flow	-2.37B	-2.08B	-6.95B	-35.30M	-566.10M
Financing Cash Flow	-50.81M	-45.90M	-778.60M	-1.42B	94.20M

BioNTech SE Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 91.19
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BNTX, the sentiment is Negative. The current price of 91.19 is below the 20-day moving average (MA) of 103.24, below the 50-day MA of 105.97, and below the 200-day MA of 104.67, indicating a bearish trend. The MACD of -4.46 indicates Positive momentum. The RSI at 35.98 is Neutral, neither overbought nor oversold. The STOCH value of 39.31 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BNTX.

BioNTech SE Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
UTHR	85 Outperform	$23.50B	16.17	19.30%	―	13.50%	17.16%
INCY	75 Outperform	$18.42B	14.98	29.15%	―	18.09%	3563.21%
ROIV	69 Neutral	$20.08B	-14.22	-18.32%	―	-83.82%	-109.22%
GMAB	66 Neutral	$16.03B	19.82	14.32%	―	24.98%	127.06%
MRNA	58 Neutral	$20.76B	―	-30.15%	―	-56.00%	-38.95%
BNTX	57 Neutral	$22.92B	―	-6.03%	―	7.04%	-25.24%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

BioNTech SE Corporate Events

BioNTech Posts 2025 Loss but Leans on Strong Cash and Late-Stage Oncology Pipeline

BioNTech reported on March 10, 2026, that its 2025 revenues rose slightly to €2.87 billion, but it swung to a full-year IFRS net loss of €1.14 billion, or €4.70 per diluted share, mainly due to declining COVID-19 vaccine demand and higher operating costs. The company highlighted a strong cash position of €17.2 billion to support a late-stage oncology pipeline, including intensified development of the PD-L11/VEGF-A bispecific pumitamig with Bristol Myers Squibb, and guided 2026 revenues to €2.0–2.3 billion alongside elevated R&D and SG&A spending, while announcing that co-founders Ugur Sahin and Özlem Türeci plan a management transition by end-2026 as they establish an independent next-generation mRNA firm.

Fourth-quarter 2025 revenue fell to €907.4 million from €1.19 billion a year earlier, with quarterly and full-year results pressured by lower COVID-19 vaccine sales and higher other operating expenses linked to settlements, pipeline prioritization and FX effects. Nevertheless, BioNTech said 2025 marked strong execution with multiple programs advancing into late-stage development and expects 2026 to be a catalyst-rich year with six key oncology data readouts that could accelerate its shift away from pandemic-era dependence toward a broader, oncology-led product portfolio.

The most recent analyst rating on (BNTX) stock is a Buy with a $134.00 price target. To see the full list of analyst forecasts on BioNTech SE stock, see the BNTX Stock Forecast page.

BioNTech Co-Founders to Launch Independent mRNA Venture as Company Refocuses on Late-Stage Pipeline

On March 10, 2026, BioNTech announced that co-founders Ugur Sahin and Özlem Türeci will establish an independent biotechnology company dedicated to next-generation mRNA innovations, with a management transition targeted by the end of 2026. BioNTech plans to transfer certain rights and mRNA technologies to the new venture in exchange for a minority stake and potential milestone and royalty streams, while preserving opportunities for future collaboration on combination therapies.

The move is part of BioNTech’s strategy to sharpen its focus on developing and commercializing its expanding late-stage pipeline, including immunomodulators, ADCs and mRNA candidates, as it works toward becoming a commercial multi-product company by 2030. The company said its existing clinical programs, including its COVID-19 vaccine franchise and an expected 15 Phase 3 oncology trials by year-end 2026, will remain unaffected, and its supervisory board has begun searching for successors to ensure leadership continuity and operational stability during the founders’ transition.

The most recent analyst rating on (BNTX) stock is a Buy with a $134.00 price target. To see the full list of analyst forecasts on BioNTech SE stock, see the BNTX Stock Forecast page.

BioNTech Adds Chief People Officer to Management Board to Support Oncology Growth Strategy

On January 28, 2026, BioNTech SE announced that its Supervisory Board has appointed seasoned HR executive Kylie Jimenez to the newly created role of Chief People Officer on the Management Board, effective March 1, 2026. Based at the company’s Mainz headquarters, Jimenez will lead BioNTech’s global people strategy—covering talent attraction, development and retention, as well as fostering an inclusive culture—in support of its plan to transform into a multi-product oncology company by 2030. With more than two decades of international experience at Georg Fischer, Toyota, Johnson & Johnson and General Mills, her appointment signals a strategic emphasis on building organizational capabilities and operational excellence, highlighting the central role of human capital in sustaining BioNTech’s long-term growth and value creation for shareholders, employees and patients.

The most recent analyst rating on (BNTX) stock is a Hold with a $121.00 price target. To see the full list of analyst forecasts on BioNTech SE stock, see the BNTX Stock Forecast page.

BioNTech Outlines 2026 Strategy and Milestones at J.P. Morgan Healthcare Conference

On January 13, 2026, BioNTech SE delivered a strategic business update at the 44th J.P. Morgan Healthcare Conference in San Francisco, outlining its key focus areas and expected milestones for 2026. Management highlighted ongoing execution of a strategy built on its COVID-19 vaccine franchise, a growing portfolio of more than 25 Phase 2 and 3 oncology trials and 16 clinical programs overall, and continued investment in infectious-disease candidates and AI-enabled R&D, signaling that the company intends to leverage its strong financial position and market leadership in COVID-19 vaccines to advance oncology assets and consolidate its position as a leading integrated mRNA and immunotherapy player.

The most recent analyst rating on (BNTX) stock is a Buy with a $143.00 price target. To see the full list of analyst forecasts on BioNTech SE stock, see the BNTX Stock Forecast page.

BioNTech Maps Out Catalyst-Rich 2026 Oncology Agenda at J.P. Morgan Healthcare Conference

On January 12, 2026, BioNTech SE announced that it will present a strategic business update at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026, outlining a catalyst-rich 2026 centered on rapid advancement of its oncology pipeline and multiple late-stage clinical milestones. Management highlighted plans to have 15 Phase 3 oncology trials underway by year-end, including six new Phase 3 initiations, and expects seven late-stage trial readouts in 2026 across immunomodulators, ADCs and mRNA cancer immunotherapies, alongside early-stage combination data that could shape future regulatory and launch strategies. Backed by a preliminary €17.2 billion cash and securities position, ongoing COVID-19 vaccine revenues, and a network of strategic partners such as Bristol Myers Squibb, Genentech, Duality Biologics and others, BioNTech is positioning itself to transition from a single-product COVID-19 vaccine leader into a financially well-capitalized, multi-product oncology company with at least 17 late-stage data readouts anticipated by 2030 and multiple prospective product launches across several cancer indications.

The most recent analyst rating on (BNTX) stock is a Buy with a $134.00 price target. To see the full list of analyst forecasts on BioNTech SE stock, see the BNTX Stock Forecast page.

BioNTech Completes CureVac Takeover and Updates Articles of Association

On January 6, 2026, BioNTech SE reported that CureVac N.V. had completed a previously announced post-offer reorganization related to BioNTech’s exchange offer for all outstanding CureVac shares, resulting in BioNTech becoming the sole owner of CureVac’s business operations and eliminating CureVac’s public shareholder base. In parallel with this transaction, BioNTech amended its Articles of Association—effective December 30, 2025—including updated provisions on share capital and authorization for future capital increases, steps that consolidate control over the acquired CureVac business and provide additional corporate and financing flexibility for BioNTech’s ongoing growth and investment strategy.

The most recent analyst rating on (BNTX) stock is a Buy with a $134.00 price target. To see the full list of analyst forecasts on BioNTech SE stock, see the BNTX Stock Forecast page.

BioNTech Completes CureVac Acquisition to Bolster mRNA Leadership

On December 18, 2025, BioNTech SE announced it had closed its acquisition of CureVac N.V., completing an exchange offer in which approximately 86.75% of CureVac’s outstanding shares were tendered, with a compulsory acquisition of the remaining shares expected in January 2026 and the subsequent delisting of CureVac. The deal is designed to strengthen BioNTech’s already significant position in the global mRNA field by adding CureVac’s technologies in mRNA design, delivery formulations and manufacturing, supporting BioNTech’s oncology strategy and consolidating two of Germany’s pioneering mRNA players under one umbrella; CureVac will initially continue operating under its existing processes while BioNTech’s leadership, now also forming CureVac’s management board, undertakes strategic and scientific analyses to define the combined group’s future organization and portfolio, with implications for a more integrated and potentially more competitive mRNA innovation platform.

The most recent analyst rating on (BNTX) stock is a Buy with a $134.00 price target. To see the full list of analyst forecasts on BioNTech SE stock, see the BNTX Stock Forecast page.